In a study posted to the bioRxiv* preprint server, a team of researchers from the United States evaluated the protective effect of the preclinical version of the current Moderna Omicron-targeted ...
In this ongoing phase 2–3, placebo-controlled trial, we randomly assigned healthy adolescents (12 to 17 years of age) in a 2:1 ratio to receive two injections of the mRNA-1273 vaccine (100 μg in each) ...
Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based ...
In a recent study posted to the medRxiv* preprint server, researchers evaluated the messenger ribonucleic acid (mRNA)-1273 vaccine effectiveness (VE) against severe acute respiratory syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results